‹ BackThe Newspaper EditionFront PageExit to modern site ›
Liberty Bell Report

Health & Medicine

A New Daily Pill for Women Whose Breast Cancer Outsmarts Hormone Therapy: What the FDA's Approval of Wilserdly Means

Roche's giredestrant, taken with everolimus, cut the risk of cancer worsening or death by 62 percent in women with an ESR1 mutation. Here is who qualifies and what to ask your doctor.

By ELENA VASQUEZStaff Correspondent · WASHINGTON · Nov 18, 3:30 PM · 3 min. read

Illustration: A sunlit American farmhouse kitchen table in the early morning, a single small white pill beside a glass of water and a pink ribbon, an open Bible and a vase of fresh garden flowers nearby, a folded quilt on a chair, soft…

Illustration · Liberty Bell Report

Women whose advanced breast cancer has stopped responding to hormone therapy have a new option. The Food and Drug Administration has approved Wilserdly, a once-daily pill from Roche and its U.S. unit Genentech, for a group of patients whose tumors carry a common resistance mutation, Newsweek reported.

The drug, known generically as giredestrant, was approved on Nov. 16 for use together with everolimus, an existing cancer medicine, according to Roche. It is meant for adults with estrogen receptor-positive, HER2-negative breast cancer that has spread or advanced and that carries a change in the ESR1 gene. Patients qualify if their cancer came back during or after hormone-based therapy following surgery, or if it worsened on at least one hormone-based treatment after it spread.

For families who have watched a loved one move from one treatment to the next, the approval adds another pill that can be taken at home rather than another round of infusions.

What the Trial Found

The approval rests on a phase 3 study called evERA, which compared giredestrant plus everolimus against a doctor's choice of standard hormone therapy plus everolimus. The trial randomly assigned 373 patients, with 183 receiving giredestrant at 30 milligrams once a day and 190 receiving standard hormone therapy, and every patient also took everolimus daily.

In patients with the ESR1 mutation, the giredestrant combination cut the risk of the cancer worsening or of death by 62 percent compared with the standard approach, Roche said. Median progression-free survival, the time patients lived without their cancer growing, was about 10 months on giredestrant versus about 5.5 months on the comparison treatment, according to CURE.

Tumors also shrank more often. Newsweek reported that the new combination shrank tumors in 27 percent of cases, compared with 14 percent for standard hormone therapy.

Across all patients in the study, including those without the mutation, the median was 8.8 months versus 5.5 months, a 44 percent reduction in risk, CURE reported. The FDA's approval is limited to patients with the ESR1 mutation, the group where the benefit was largest.

Side Effects and What Is Still Unknown

No drug comes without trade-offs. In the trial, 17 percent of patients on the giredestrant combination stopped treatment because of side effects, compared with 11.8 percent in the comparison group, according to CURE. Researchers noted that patients on giredestrant stayed on treatment longer, which can affect how side effects are counted.

Overall survival, the measure of whether patients live longer, was not yet mature when the results were analyzed, though early data showed a positive trend. Patients and doctors will be watching for those longer-term results.

To find out whether a patient qualifies, the FDA also approved a companion blood test, FoundationOne Liquid CDx, which looks for the ESR1 mutation in a simple blood draw.

Giredestrant belongs to a newer family of drugs called oral SERDs, which block and break down the estrogen receptor that fuels many breast cancers. It joins other recent approvals in the class, including Eli Lilly's imlunestrant, sold as Inluriyo, which the FDA approved in September 2025 for ESR1-mutated advanced breast cancer.

Roche is not finished. The FDA is also reviewing giredestrant under priority review as a treatment after surgery for early breast cancer, with a decision expected by Nov. 30, AJMC reported. If approved, that would move the drug earlier in treatment, when the goal is preventing the cancer from coming back.

Questions to Ask Your Doctor

For a woman living with advanced breast cancer, or for the husband, daughter or friend who sits beside her at appointments, a few questions can help make the most of this news:

Has my tumor been tested for an ESR1 mutation, and should I have the blood test now that my cancer has progressed? Mutations like this can appear after months or years on hormone therapy, so an earlier test may not tell the whole story.

How does giredestrant compare with the other oral options for my situation, and what side effects of everolimus should I watch for at home?

Will my insurance cover the drug and the test, and is there a patient assistance program if it does not?

Are there clinical trials I might qualify for if this treatment stops working?

Every new approval represents years of work by researchers and the courage of the women who volunteered for the trial. For patients who have already fought hard, a few more months of good days with the people they love is not a small thing.

Sources

  1. Newsweek: FDA Approves New Breast Cancer Pill After Hormone Therapy Stops Working (link)
  2. Roche: FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer (link)
  3. AJMC: FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer (link)
  4. CancerNetwork: FDA Approves Giredestrant/Everolimus for ER+, HER2-, ESR1-Mutated Breast Cancer (link)
  5. CURE: Giredestrant Combo Cuts Progression Risk by 44% in Advanced Breast Cancer (link)
  6. U.S. Food and Drug Administration: FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (link)

— 30 —

Read this story on the full website, with comments »

Also in Today’s Edition

Previous pageHealth & MedicineTurn the pageA Daily Pill for Alzheimer's? A Viagra-Family Drug Slowed…